Document is current
Any future updates will be listed below
-
Authors
De Sloovere, Veerle
Mebis, Liese
Wouters, Pieter
Guïza, Fabian
Boonen, Eva
Bourgeois, Marc
Dubois, Jasperina
Ledoux, Didier
Lormans, Piet
Maréchal, Hugues
Van der Hauwaert, Emmanuel
Depreitere, Bart
Meyfroidt, Geert https://orcid.org/0000-0003-4259-3935
-
Funding
Funding for this research was provided by:
Pfizer (Pfizer Grant 53234057)
Established Investigator Award 2016, European Society of Intensive Care Medicine
Universitaire Ziekenhuizen Leuven, KU Leuven (Clinical Council for Research, Education (KOOR))
Fonds Wetenschappelijk Onderzoek (Senior Clinicial Investigator Grant 1843123N)
- License Information
-
More Information
Article History
Received: 2 February 2024
Accepted: 6 April 2025
First Online: 28 May 2025
Declarations
:
: The protocol and informed consent forms have been approved by the Research Ethics Committee of the UZ/KU Leuven, acting as the central ethics committee, and by the local ethics committees of all participating centres for local participation. An annual progress report will be submitted to the Ethics Committee and the National Competent Authority, including an update on the number of participants enrolled in each centre, and an overview of serious adverse events.
: Written informed consent was obtained from the patient’s next of kin for all study patients.
: None.
